Amerisourcebergen (ABC) Stock Price
Amerisourcebergen Price
Over the last 19 years Amerisourcebergen grew revenue by 8.6% annually, reaching 238.59 B USD. For Amerisourcebergen, the net margin of 0.7% is broadly stable versus 1.0% a few years ago. At today's price the dividend yield works out to roughly 1.01%. The dividend has grown at 16.6% per year over the past 19 years. The consensus 12-month price target for Amerisourcebergen is 213.18 USD, about 15.0% above where the stock trades today. Of 21 analysts, 14 rate the stock a buy — an overall Buy consensus.
Amerisourcebergen stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Amerisourcebergen over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Amerisourcebergen stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Amerisourcebergen's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Amerisourcebergen Price |
|---|
Amerisourcebergen Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Amerisourcebergen Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| DIVIDENDDIV.USD |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 87.96 | 119.57 | 135.96 | 146.85 | 153.14 | 167.94 | 179.59 | 189.89 | 213.99 | 238.59 | 259.50 | 274.53 | 289.40 | 318.56 | 333.35 | 349.93 |
| 10.66 | 35.94 | 13.71 | 8.01 | 4.29 | 9.66 | 6.94 | 5.74 | 12.69 | 11.49 | 8.76 | 5.79 | 5.42 | 10.08 | 4.64 | 4.97 |
| 2.85 | 2.49 | 2.60 | 2.91 | 2.97 | 2.75 | 2.86 | 2.73 | 3.24 | 3.48 | 3.48 | 3.48 | 3.48 | 3.48 | 3.48 | 3.48 |
| 2.51 | 2.98 | 3.53 | 4.27 | 4.55 | 4.61 | 5.14 | 5.19 | 6.94 | 8.30 | 9.02 | 9.55 | 10.06 | 11.08 | 11.59 | 12.17 |
| 0.90 | 0.78 | 0.42 | 1.53 | 2.02 | 1.44 | 1.12 | 2.04 | 2.35 | 2.37 | 3.31 | 3.54 | 3.79 | 3.97 | 4.22 | 4.46 |
| 1.02 | 0.65 | 0.31 | 1.04 | 1.32 | 0.86 | 0.63 | 1.07 | 1.10 | 0.99 | 1.27 | 1.29 | 1.31 | 1.25 | 1.26 | 1.28 |
| 0.43 | 0.28 | -0.13 | 1.43 | 0.41 | 1.66 | 0.86 | -3.40 | 1.54 | 1.70 | 2.40 | 2.58 | 2.85 | 3.10 | 3.39 | 3.65 |
| -39.69 | -36.26 | -148.55 | -1,164.93 | -70.99 | 300.48 | -48.43 | -497.54 | -145.28 | 10.33 | 41.11 | 7.76 | 10.26 | 8.92 | 9.29 | 7.55 |
| – | – | – | – | – | – | – | – | – | – | 1.94 | 1.94 | 1.94 | – | – | – |
| 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 | 118.00 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Amerisourcebergen generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Amerisourcebergen retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Amerisourcebergen's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Amerisourcebergen has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Amerisourcebergen's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Amerisourcebergen stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Amerisourcebergen Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Amerisourcebergen business model & stock analysis
Amerisourcebergen SWOT Analysis
Strengths
1. Established market presence: AmerisourceBergen Corp has a strong foothold in the pharmaceutical distribution industry, benefiting from its long-standing history and extensive network.
2. Diverse product portfolio: The company offers a comprehensive range of pharmaceutical products, including generic drugs and specialty medications, enabling it to cater to diverse customer needs.
3. Strong partnerships: AmerisourceBergen has formed strategic alliances with key industry players, such as pharmaceutical manufacturers, pharmacies, and healthcare providers, enhancing its competitive advantage.
Weaknesses
1. Dependence on key customers: AmerisourceBergen relies heavily on a few major customers for a significant portion of its revenue. This dependency exposes the company to potential risks if these customers reduce their orders or seek alternative distribution channels.
2. Vulnerability to industry regulations: As a healthcare-related company, AmerisourceBergen is subject to stringent regulations and policies that can impact its operations and profitability. Changes in legislation or government policies pose a risk to the company's growth.
3. Potential supply chain disruptions: Any disruption in the supply chain, such as delays in product delivery or shortages, could negatively impact AmerisourceBergen's reputation and customer relationships.
Opportunities
1. Growing demand for specialty drugs: The increasing prevalence of chronic diseases and advancements in pharmaceutical research present an opportunity for AmerisourceBergen to expand its specialty drug offerings and capture a larger market share.
2. Digitalization and technology advancements: The adoption of technology in healthcare, such as e-commerce platforms and data analytics, offers opportunities for AmerisourceBergen to improve operational efficiencies and enhance customer experience.
3. International expansion: Expanding into emerging markets or through partnerships with global pharmaceutical companies can provide AmerisourceBergen with access to new customer bases and revenue streams.
Threats
1. Pricing pressures: The pharmaceutical distribution industry is highly competitive, leading to potential pricing pressures from customers and suppliers. Fee compression and margin erosion pose risks to AmerisourceBergen's profitability.
2. Counterfeit and illegal drugs: The presence of counterfeit or illegal drugs in the market poses a threat to AmerisourceBergen's reputation and could result in legal and regulatory issues.
3. Industry consolidation: Mergers and acquisitions within the pharmaceutical distribution industry can create larger competitors and disrupt AmerisourceBergen's market position and growth strategies.
Amerisourcebergen Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Amerisourcebergen Segments
Amerisourcebergen Revenue by Segment
3 Years
5 Years
10 Years
Max
Details
Amerisourcebergen Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Amerisourcebergen historical P/E ratio, EBIT multiple, and P/S ratio
Amerisourcebergen annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Amerisourcebergen shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Amerisourcebergen stock splits
Amerisourcebergen Dividend History
23 years of dividend payments
Amerisourcebergen dividend history and estimates
Max
Details
Amerisourcebergen dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Amerisourcebergen forecasts and price targets in August 2026
Analyst Price Targets 2026Amerisourcebergen Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 1/30/2024 | 2.93USD | - | 66.49 BUSD | - | 2024 Q1 |
| 8/1/2023 | 2.83USD | - | 64.36 BUSD | - | 2023 Q3 |
| 5/2/2023 | 3.29USD | - | 61.56 BUSD | - | 2023 Q2 |
| 1/31/2023 | 2.63USD | - | 63.58 BUSD | - | 2023 Q1 |
| 11/3/2022 | 2.60USD | - | 61.45 BUSD | - | 2022 Q4 |
| 8/3/2022 | 2.59USD | - | 59.91 BUSD | - | 2022 Q3 |
| 5/4/2022 | 2.96USD | - | 58.13 BUSD | - | 2022 Q2 |
| 2/2/2022 | 2.60USD | - | 60.35 BUSD | - | 2022 Q1 |
| 11/4/2021 | 2.38USD | - | 58.19 BUSD | - | 2021 Q4 |
| 8/4/2021 | 2.07USD | - | 53.14 BUSD | - | 2021 Q3 |
Amerisourcebergen shareholder structure
| % | Name |
|---|---|
16.75803% | |
10.09337% | |
4.52958% | |
3.67894% | |
2.81565% | |
2.59266% |
Amerisourcebergen Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
10.30% | SEC ↗ | |
9.21% | SEC ↗ | |
8.50% | SEC ↗ | |
8.24% | SEC ↗ | |
7.30% | SEC ↗ | |
6.30% | SEC ↗ | |
6.25% | SEC ↗ | |
5.40% | SEC ↗ | |
5.40% | SEC ↗ | |
5.40% | SEC ↗ |
Amerisourcebergen Supply Chain
Amerisourcebergen Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.75 | 0.77 | 0.87 | ||
| 2 | 0.95 | 0.96 | 0.83 | ||
| 3 | 0.97 | 0.75 | 0.74 | ||
| 4 | 0.86 | 0.77 | 0.70 | ||
| 5 | -0.05 | 0.31 | 0.66 |
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | -0.30 | -0.76 | — | ||
| 2 | 0.87 | 0.84 | — | ||
| 3 | Teva Pharmaceutical Industries Limited | -0.86 | — | — | |
| 4 | Takeda Pharmaceutical Company Limited | -0.27 | -0.74 | — | |
| 5 | WPT Industrial Real Estate Investment Trust | 0.93 | 0.96 | — |
Frequently asked questions about Amerisourcebergen
AmerisourceBergen Corp is a leading global pharmaceutical sourcing and distribution company. Its business model primarily focuses on providing pharmaceutical products and services to various healthcare providers, including hospitals, pharmacies, and physicians. As a key player in the healthcare supply chain, AmerisourceBergen operates through three main segments: Pharmaceutical Distribution Services, Global Commercialization Services, and Animal Health. Through these segments, the company offers a comprehensive range of services, including sourcing, packaging, logistics, and technology solutions. AmerisourceBergen Corp collaborates with pharmaceutical manufacturers to ensure the efficient delivery of vital medications and healthcare products to patients worldwide.
AmerisourceBergen Corp primarily operates in the pharmaceutical distribution industry.
The main competitors of AmerisourceBergen Corp in the market include McKesson Corporation and Cardinal Health Inc. These companies are key players in the pharmaceutical distribution industry, providing similar services and products. AmerisourceBergen Corp competes with these rivals in terms of market share, customer relationships, and supply chain management. These competitors also operate on a global scale, catering to the needs of healthcare providers and pharmaceutical manufacturers. Overall, AmerisourceBergen faces strong competition from McKesson Corporation and Cardinal Health Inc in its efforts to maintain its position as a leading player in the pharmaceutical distribution market.
AmerisourceBergen Corp, founded in 2001, is a global healthcare solutions company based in the United States. It specializes in pharmaceutical sourcing and distribution services, serving both pharmaceutical manufacturers and healthcare providers. With its extensive network of distribution centers, AmerisourceBergen offers a wide range of products and services to support patient care and deliver vital medications. The company has a rich history of growth and innovation, expanding its operations globally and establishing itself as a leader in the healthcare industry. AmerisourceBergen continues to evolve and adapt to the changing needs of the healthcare landscape, striving to improve patient outcomes and advance the delivery of healthcare services.
AmerisourceBergen Corp, a leading global healthcare solutions company, has achieved several significant milestones. The company has consistently expanded its market reach through strategic acquisitions and partnerships, solidifying its position as a major player in the pharmaceutical distribution industry. AmerisourceBergen Corp has also demonstrated its commitment to innovation by adopting advanced technologies and enhancing its digital capabilities. Furthermore, the company's strong financial performance, consistent revenue growth, and successful execution of its business strategies have contributed to its continuous success and recognition as a Fortune 11 company. AmerisourceBergen Corp's dedication to serving the healthcare needs of patients and providing exceptional value to its customers have allowed it to become a trusted partner in the industry.
AmerisourceBergen Corp is primarily present in the United States, one of the largest pharmaceutical markets globally. With headquarters in Pennsylvania, the company operates in various regions across the US, including key cities like California, New York, Texas, and Florida. AmerisourceBergen provides pharmaceutical distribution and related services to a wide range of healthcare providers, including hospitals, pharmacies, and physician practices. With a strong presence across the American healthcare landscape, AmerisourceBergen Corp plays a vital role in ensuring the efficient and reliable distribution of pharmaceutical products throughout the United States.
AmerisourceBergen Corp represents a strong commitment to integrity, innovation, and collaboration. The company values client relationships and aims to provide superior service by fulfilling the healthcare needs of their customers. With a mission to improve patient access to pharmaceuticals and medical products, AmerisourceBergen Corp operates under the corporate philosophy that emphasizes reliable distribution networks, cutting-edge technology solutions, and industry expertise. By leveraging their extensive network, they work towards delivering exceptional value to healthcare providers and pharmaceutical manufacturers. AmerisourceBergen Corp strives to foster a culture of trust, integrity, and transparency, ensuring sustainable growth and success in the healthcare industry.
Analysts currently set an average price target of 213.76 USD for the Amerisourcebergen stock (median: 213.18 USD), implying +15.3 % versus the latest price. The consensus is based on 21 analyst ratings.
20 analysts currently rate the Amerisourcebergen stock: 13 recommend buying, 7 holding and 0 selling.
Converted at the current exchange rate, the Amerisourcebergen share trades at 160.31 EUR (185.41 USD).
The Amerisourcebergen share (ABC) is listed on 8 stock exchanges, including: NYSE (ABC), XETRA (ABG.DE), Frankfurt (ABG.F), München (ABG.MU), Düsseldorf (ABG.DU), London (0HF3.L), London (0HF3.L), SIX (Zürich) (ABGCHF.SW).
AmerisourceBergen Corp is an international company based in the USA that specializes in providing innovative solutions in the healthcare industry. The company offers a wide range of products and services that enable healthcare facilities to operate more efficiently and improve patient care. The business model of AmerisourceBergen Corp is based on three main business areas: 1. Pharmaceutical Distribution: The company is one of the largest pharmaceutical distributors in North America and offers a wide range of products and services to meet the demand for pharmaceuticals and medications. This includes specialty pharmaceuticals, biosimilars, and generics. 2. Outsourcing Services: AmerisourceBergen offers a variety of outsourcing services, including medication manufacturing, supply chain support, and consultation and training for healthcare professionals. 3. Value Assessment: Lastly, AmerisourceBergen provides value assessment services that enable customers to better understand and communicate the impact and benefits of their products. Together, these three business areas form the foundation of AmerisourceBergen's business model and enable the company to offer a variety of products and services to improve the quality of patient care and efficiency in the healthcare industry. One example of the products offered by AmerisourceBergen is oncology therapies. The company is a major provider of cancer medications in North America. It also works closely with insurance companies and other partners to ensure that cancer patients have access to necessary treatments and services. This product is an example of how AmerisourceBergen combines its core business areas to meet the demand for innovative solutions in healthcare. SEO-optimized terms found in this text include "pharmaceutical distributors," "outsourcing services," "value assessment services," and "oncology therapies." These terms are used to clarify the topic of the text and increase traffic to the AmerisourceBergen website by being found by search engines. By using such key terms, the text also strengthens the online visibility of AmerisourceBergen and contributes to improving the company's online marketing strategy.
The revenue cannot currently be calculated for Amerisourcebergen.
The profit cannot currently be calculated for Amerisourcebergen.
The P/E ratio cannot be calculated for Amerisourcebergen at the moment.
The P/S cannot be calculated for Amerisourcebergen currently.
The Eulerpool Quality Score for Amerisourcebergen is 5/10.
The ISIN of Amerisourcebergen is US03073E1055. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Amerisourcebergen is 766149. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Amerisourcebergen is ABC. The ticker symbol is used to trade Amerisourcebergen shares on the stock exchange.
Over the past 12 months, Amerisourcebergen paid a dividend of 1.87 USD . This corresponds to a dividend yield of about 1.01 %. For the coming 12 months, Amerisourcebergen is expected to pay a dividend of 1.94 USD.
The current dividend yield of Amerisourcebergen is 1.01 %.
Amerisourcebergen pays a dividend, distributed in the months of , , , .
Amerisourcebergen paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 1.94 USD are expected. This corresponds to a dividend yield of 1.05 %.
Amerisourcebergen is assigned to the 'Health' sector.
To receive the latest dividend of Amerisourcebergen from amounting to 0.49 USD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
In the year 2025, Amerisourcebergen distributed 1.94 USD as dividends.
The dividends of Amerisourcebergen are distributed in USD.
Amerisourcebergen stock
Amerisourcebergen Peer Group
Amerisourcebergen Ticker
Amerisourcebergen FIGI
All fundamentals and in-depth analysis of Amerisourcebergen
Our stock analysis for Amerisourcebergen stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amerisourcebergen. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.